Evidence map›Paper›PMID 29155899›Full record

ArticlePLoS pathogens2017

Subtle variation within conserved effector operon gene products contributes to T6SS-mediated killing and immunity.

Christopher J Alteri, Stephanie D Himpsl, Kevin Zhu, Haley L Hershey, Ninette Musili, Jessa E Miller, Harry L T Mobley

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Into the understanding the multicellular lifestyle ofFrontiers in cellular and infection microbiology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Heliyon · 2020
    Article
  15. Article
  16. Article
  17. TheProceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christopher J AlteriDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.ORCID http://orcid.org/0000-0002-6367-5684
Stephanie D HimpslDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.
Kevin ZhuDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.ORCID http://orcid.org/0000-0003-0521-0819
Haley L HersheyDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.
Ninette MusiliDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.ORCID http://orcid.org/0000-0002-3358-1521
Jessa E MillerDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.
Harry L T MobleyDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.ORCID http://orcid.org/0000-0001-9195-7665
University of Michigan · US

Funding

Reciprocal Control of Motility and Adherence in UTIR01AI059722 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PEARSON, MELANIE M. · 2005 to 2024
$7.4M
MOLECULAR PATHOGENESIS OF E COLI UTIR01AI043363 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOBLEY, HARRY L. · 1998 to 2012
$3.4M
Vaccine to prevent E. coli urinary tract infectionR56AI043363 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOBLEY, HARRY L. · 2014 to 2014
$351k
NIAID NIH HHS R01 AI043363NIAID NIH HHS R01 AI059722NIAID NIH HHS R56 AI043363
6 · The paper itself

Abstract

Type VI secretion systems (T6SS) function to deliver lethal payloads into target cells. Many studies have shown that protection against a single, lethal T6SS effector protein requires a cognate antidote immunity protein, both of which are often encoded together in a two-gene operon. The T6SS and an effector-immunity pair is sufficient for both killing and immunity. HereIn this paper we describe a T6SS effector operon that differs from conventional effector-immunity pairs in that eight genes are necessary for lethal effector function, yet can be countered by a single immunity protein. In this study, we investigated the role that the PefE T6SS immunity protein plays in recognition between two strains harboring nearly identical effector operons. Interestingly, despite containing seven of eight identical effector proteins, the less conserved immunity proteins only provided protection against their native effectors, suggesting that specificity and recognition could be dependent on variation within an immunity protein and one effector gene product. The variable effector gene product, PefD, is encoded upstream from pefE, and displays toxic activity that can be countered by PefE independent of T6SS-activity. Interestingly, while the entire pef operon was necessary to exert toxic activity via the T6SS in P. mirabilis, production of PefD and PefE alone was unable to exert this effector activity. Chimeric PefE proteins constructed from two P. mirabilis strains were used to localize immunity function to three amino acids. A promiscuous immunity protein was created using site-directed mutagenesis to change these residues from one variant to another. These findings support the notion that subtle differences between conserved effectors are sufficient for T6SS-mediated kin discrimination and that PefD requires additional factors to function as a T6SS-dependent effector.

Indexed as

OperonBacterial ProteinsEscherichia coliMutagenesis, Site-DirectedProteus mirabilisTranscription FactorsType VI Secretion SystemsVibrio choleraeBacterial ProteinsTranscription FactorsType VI Secretion Systems

Identifiers

PMID29155899
PMCPMC5714391
OpenAlexW2769469554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.